1) 河合真 (著), 香坂俊 (監修). 極論で語る睡眠医学. 丸善出版, 2016.
2) Waldvogel HJ, Baer K, et al. Distribution of GABAA receptor subunits in the human brain. In : Monti JM, Pandi-Perumal SR, Mohler H, editors. gABA and sleep : molecular, functional and clinical aspects. Basel : Springer Basel ; 2010. p.73-93.
3) Bourin M. The GABAA receptor and benzodiazepine acceptor site. SOJ Pharm Pharm Sci. 2018 ; 5 (2) : 1-5.
4) Griebel G, Perrault G, et al. New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (ω) receptor subtypes. Psychopharmacology. 1999 ; 146 (2) : 205-13.
5) Sanger DJ, Benavides J, et al. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors : evidence for the functionalsignificance of receptor subtypes. Neuroscience & biobehavioralreviews. 1994 ; 18 (3) : 355-72.
6) Huedo-Medina TB, Kirsch I, et al. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia : meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012 ; 345.
7) 近藤英明, 神林崇, 他. オレキシン神経系とナルコレプシー. 日本内科学会雑誌. 2006 ; 95 (4) : 748-55.
8) 飯島節. 高齢者の夜間せん妄の管理. 日本老年医学会雑誌. 2006 ; 43 (4) : 428-30.
9) Hatta K, Kishi Y, et al. Preventive effects of suvorexant on delirium : a randomized placebo-controlled trial. J Clin Psychiatry. 2017 ; 78 (8) : e970-9.
10) Xu S, Cui Y, et al. Suvorexant for the prevention of delirium : A meta-analysis. Medicine. 2020 ; 99 (30).
11) 谷内一彦, 櫻井映子, 他. 抗ヒスタミン薬の薬理学. 日本耳鼻咽喉科学会会報. 2009 ; 112 (3) : 99-103.
12) Richardson GS, Zee PC, et al. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med. 2008 15 ; 4 (5) : 456-61.
13) Sack RL, Hughes RJ, et al. Sleep-promoting effects of melatonin : at what dose, in whom, under what conditions, and by what mechanisms?. Sleep. 1997 ; 20 (10) : 908-15.